Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized trial of allogeneic hematopoietic stem cell transplantation versus standard chemotherapy in first-remission intermediate-risk AML
2010-019377-15Phase 3Terminated
- Sponsor
- Technische Universität Dresden
- Start
- Apr 2010
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of hematopoietic stem cells in acute myeloid leukemia (AML) (2 arms), sponsored by Technische Universität Dresden. Primary endpoint: Overall survival. Started Apr 2010; status: terminated.
02
Drugs
hematopoietic stem cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on 2010-019377-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-019377-15.